Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-mAb-B43.13
- Development stage
- Preclinical
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**89Zr-DFO-mAb-B43.13** is a preclinical CA125-targeted radioimmunoconjugate developed for immuno-positron emission tomography. It comprises the anti-CA125 monoclonal antibody mAb B43.13 conjugated to the desferrioxamine chelator and labeled with zirconium-89. By selectively binding mucin-16, it enables noninvasive visualization of CA125-positive high-grade serous ovarian cancer and metastatic lymph nodes. In OVCAR3 ovarian-cancer xenograft models, the tracer delineated tumors from 24 hours after administration and showed substantial uptake in tumor and metastatic lymph-node tissue. ([jnm.snmjournals.org](https://jnm.snmjournals.org/content/57/5/771))
- Other names
- 89Zr-DFO-MAb-B43.1389Zr-labeled mAb-B43.13
02
Targets
MUC16 (Mucin-16)
Beyond the preview
Go deeper on 89Zr-DFO-mAb-B43.13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-mAb-B43.13.